Newsroom
July 11, 2023
1
min
Press Release

Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria's Novel Biologic to Treat Pulmonary Sarcoidosis

CHICAGO (**July 11, 2023**)—Perkins Coie is pleased to have advised Xentria Inc., a clinical-stage biotherapeutics company dedicated to developing novel therapeutics to address unmet medical needs, in its exclusive multi-year licensing agreement with Meitheal Pharmaceuticals, Inc., to commercialize its novel biologic XTMAB-16 for pulmonary sarcoidosis in North America.

The Perkins Coie team was led by Chicago-based Corporate & Securities Partner John Schreiner and Intellectual Property Partner David Fournier, who serves as chair of the firm's Patent Prosecution & Portfolio Counseling practice, and also included San Diego Partner Mark Wicker, Chicago Partner Sarah Flotte, Seattle Counsel Allison Glasunow, and San Diego Associate Alina Litoshyk.

In a deal valued in excess of \$600 million, Meitheal will obtain sole rights to market the biologic in North America, with Xentria continuing to oversee its clinical development and maintaining the rights to market the product in all other countries subject to a right of first offer.

XTMAB-16, a lead candidate of Xentria and an anti-TNF? monoclonal antibody, will be tested in Phase II clinical trials later this year to analyze its ability to reduce an inflammatory response related to pulmonary sarcoidosis.

Perkins Coie is a leading global law firm, dedicated to helping the world's most innovative companies solve the legal and business challenges of tomorrow. Learn about our work and values here.

Media Inquiries: Please email <u>Justin Cole</u>, Head of Media Relations.

Contact



John P. Schreiner

Partner
JSchreiner@perkinscoie.com 312.324.8475



David B. Fournier

Partner

DFournier@perkinscoie.com 312.324.8643



Mark R. Wicker

Partner

MWicker@perkinscoie.com 858.720.5733



Allison M. Glasunow, Ph.D.

Partner

AGlasunow@perkinscoie.com 206.359.3199



Alina Litoshyk Adams

Counsel

AAdams@perkinscoie.com 858.720.5740

Explore more in

Media inquiries